Category: Psychedelic Bulletin - Page 8 - Psychedelic Alpha

Read more about the article Psychedelic Bulletin #136: MindMed Collaborators Share Topline LSD for MDD Results; Oregon Issues Psilocybin Licences; UK Parliament to Discuss Psilocybin Rescheduling

Psychedelic Bulletin #136: MindMed Collaborators Share Topline LSD for MDD Results; Oregon Issues Psilocybin Licences; UK Parliament to Discuss Psilocybin Rescheduling

Post published:April 28, 2023
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin #135: A Misguided MDMA Price-Fixing Effort; Psilocybin Study’s Lukewarm Results; Dutch Government Forms MDMA Commission; Trouble at Empyrean?

Psychedelic Bulletin #135: A Misguided MDMA Price-Fixing Effort; Psilocybin Study’s Lukewarm Results; Dutch Government Forms MDMA Commission; Trouble at Empyrean?

Post published:April 9, 2023
Post category:Psychedelic Bulletin

Read more about the article Dispatch from ECNP New Frontiers: Psychedelics (Psychedelic Bulletin #134)

Dispatch from ECNP New Frontiers: Psychedelics (Psychedelic Bulletin #134)

Post published:March 25, 2023
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin #133: Ketamine Clinics Close with Potential Repercussions for PAT Roll-Out; Psychedelics at SXSW; Could MDMA Be Among First Beneficiaries of Faster UK Drug Approvals?

Psychedelic Bulletin #133: Ketamine Clinics Close with Potential Repercussions for PAT Roll-Out; Psychedelics at SXSW; Could MDMA Be Among First Beneficiaries of Faster UK Drug Approvals?

Post published:March 17, 2023
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin #132: COMPASS Pathways Amends Phase 3 Program; Stamets Stack Finally Patented; Learning from Zuranolone?

Psychedelic Bulletin #132: COMPASS Pathways Amends Phase 3 Program; Stamets Stack Finally Patented; Learning from Zuranolone?

Post published:March 5, 2023
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin #131: Study Turns Understanding of Psychedelic-Induced Neuroplasticity Inside Out; EU Regulators Show Interest in Psychedelics; What Next for At-Home Ketamine Therapy?

Psychedelic Bulletin #131: Study Turns Understanding of Psychedelic-Induced Neuroplasticity Inside Out; EU Regulators Show Interest in Psychedelics; What Next for At-Home Ketamine Therapy?

Post published:February 20, 2023
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin #130: Australia to Reschedule MDMA and Psilocybin; Small Pharma Reports Positive DMT Data; Journey Clinical Closes $8.5m Series A

Psychedelic Bulletin #130: Australia to Reschedule MDMA and Psilocybin; Small Pharma Reports Positive DMT Data; Journey Clinical Closes $8.5m Series A

Post published:February 3, 2023
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin #129: New Year, New Psychedelic Bills; WHO Dubs 5-MeO-DMT ‘Mebufotenin’

Psychedelic Bulletin #129: New Year, New Psychedelic Bills; WHO Dubs 5-MeO-DMT ‘Mebufotenin’

Post published:January 15, 2023
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin #128: atai Results Disappoint; MAPS Confirmatory Phase 3 Study “Successful”; New York Bill Would Legalize Psychedelics; Oregon Begins Accepting Licence Applications

Psychedelic Bulletin #128: atai Results Disappoint; MAPS Confirmatory Phase 3 Study “Successful”; New York Bill Would Legalize Psychedelics; Oregon Begins Accepting Licence Applications

Post published:January 7, 2023
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin #127: Psilocybin Shows Promise in Bipolar Disorder; Gilgamesh Raises $39m; California Decrim. Bill Returns; Canadian Province Covers Cost of PAT

Psychedelic Bulletin #127: Psilocybin Shows Promise in Bipolar Disorder; Gilgamesh Raises $39m; California Decrim. Bill Returns; Canadian Province Covers Cost of PAT

Post published:December 19, 2022
Post category:Psychedelic Bulletin

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.